Institut De Cancerologie Strasbourg Europe
- Address
- lock Available on a paid plan
Institut De Cancerologie Strasbourg Europe
The Institut De Cancerologie Strasbourg Europe is a comprehensive cancer research center conducting advanced clinical trials across a wide spectrum of oncological conditions. The institute demonstrates particular strength in precision oncology and immunotherapy-based treatments, with extensive experience in both solid tumors and hematological malignancies.
- Prostate cancer research, including castration-resistant disease, hormone-sensitive metastatic disease, and novel imaging-guided therapies with PSMA targeting agents
- Hematological malignancies including multiple myeloma, acute lymphoblastic leukemia, myelodysplastic syndromes, and various lymphoma subtypes
- Gastrointestinal cancers encompassing colorectal adenocarcinoma, neuroendocrine tumors, esophageal cancer, and anal canal carcinoma
- Breast and gynecological oncology, including hormone receptor-positive breast cancer and rare ovarian cancer subtypes
The center excels in investigating combination immunotherapy strategies, including checkpoint inhibitors combined with chemotherapy or targeted agents. Research programs span early-phase dose-finding studies through large Phase III randomized trials, with significant focus on biomarker-driven patient selection such as MSI/dMMR status, PTEN deficiency, and HER2 expression. The institute maintains active protocols in urological cancers (bladder, kidney, and prostate), rare tumors (meningioma, adrenocortical carcinoma, pediatric brain tumors), and advanced therapeutic approaches including bispecific antibodies, antibody-drug conjugates, and peptide receptor radionuclide therapy (PRRT). This comprehensive portfolio positions the center at the forefront of personalized cancer medicine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 15 of 249 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 236 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut De Cancerologie Strasbourg Europe
lock Showing 1 of 164 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20289) A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors | Bayer AG, Bayer Consumer Care AG | Phase II | Not Recruiting | Jun 2016 | Sep 2025 |
IMP list
lock Showing 1 of 249 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 19 | Unknown | 2020-10-27 | 2026-03-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.